More than three dozen attorneys general are urging the FDA to take “decisive action” against counterfeit obesity drugs.
Federal regulators say shortages of Ozempic and Wegovy have been resolved, as supplies of popular diabetes and obesity treatments continue to improve.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback